For the first time, we describe a pro-differentiation effect for AKI on a subset of sphere-enriched cancer stem-like cells and demonstrate that copy number alteration of regulatory gene-products, like HMMR/RHAMM and TPX2, can significantly impact the tumour cellular responses to these emerging therapies. The gene discussed is TPX2; the disease is neoplasm.